View AllPharmaBiotechMedical
4 October 2018
Request to re-open Glaxo ‘dual pricing’ case rejected by General Court: The end of the road for challenges to dual pricing?

Entering into agreements that erect barriers to parallel exports between EU markets is generally a...

20 September 2018
CAR-T gets the green light in Europe

On Monday 27 August, the first two CAR-T therapies were authorised for use in the...

10 September 2018
Data Privacy is going Global

No lawyer nor privacy professional can be unaware of the EU General Data Protection Regulation...

20 August 2018
Are organisms that are the product of mutagenesis subject to the GMO Directive on deliberate release?

In case C-528/16 proceedings were brought between the French agricultural union and eight associations (the...

14 August 2018
Concordia and the CMA – a drama in (at least) three parts

Last week, Concordia International released a management report in which it announced the names of six drugs...

14 August 2018
Different types of CAR-T

CAR-T cell therapy remains an exciting area in healthcare, and a potentially very lucrative one...

30 July 2018
The EMA’s clinical data publication policy: 1 year on

On 16 July 2018, the EMA published a report on the first year (Oct 2016...

4 July 2018
CJEU follows Advocate General’s Opinion to confirm the scope of the Specific Mechanism

On 21 June 2018 the CJEU gave its judgment in a preliminary reference from the...

3 July 2018
CAR-T keeps driving forward: a round-up of recent scientific and commercial developments

The pace of development in the CAR-T world, both scientific and commercial, is showing no...

20 June 2018
The CAT sets a clear framework for excessive and unfair prices in its Pfizer/Flynn judgment

The Competition Appeal Tribunal (CAT) recently gave its judgment in Pfizer and Flynn’s appeal of...

13 June 2018
Drafting leases for life sciences

Over the past decade, the UK life sciences sector has enjoyed rapid expansion, aided by...

8 June 2018
Driving immunotherapy forward: More than CAR-Ts

With two therapies already on the market and many more in the pipeline, CAR-T is...